Xilio Therapeutics, Inc. (XLO): Nasdaq/NYSE listing notice — Xilio Therapeutics transfers to Nasdaq Capital Market; extended bid price deadline to March 2026

Xilio Therapeutics, Inc.

Company received approval on Oct 2, 2025 to transfer listing from Nasdaq Global Select to Capital Market, effective Oct 6.
Transfer follows failure to meet $1.00 minimum bid price requirement for continued Global Select listing.
Nasdaq granted additional 180-day period until March 30, 2026 to regain compliance with minimum bid price.
Stock must close at $1.00+ for 10 consecutive business days to regain compliance; company evaluating options.
Common stock continues to trade under symbol XLO on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(H)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(H)

Exact text from the filing

April 8, 2025 , the Company received a letter from the Staff of Nasdaq notifying the Company of its failure to maintain the $1.00 minimum bid price required for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). In connection with the transfer to The Nasdaq Capital Market, Nasdaq granted the Company an additional 180 calendar day period, or until March 30, 2026, to regain compliance with the Minimum Bid Price Requirement. During the additional 180 calendar day grace period, the Company’s common stock must close at $1

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-229231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.